nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—CYP3A4—bone cancer	0.819	1	CbGaD
Rivaroxaban—CYP2J2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00804	0.113	CbGpPWpGaD
Rivaroxaban—CYP2J2—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00769	0.108	CbGpPWpGaD
Rivaroxaban—CYP2J2—Xenobiotics—CYP3A4—bone cancer	0.00388	0.0543	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—CYP4V2—bone cancer	0.00346	0.0484	CbGpPWpGaD
Rivaroxaban—F10—Blood Clotting Cascade—PLAU—bone cancer	0.0024	0.0335	CbGpPWpGaD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00232	0.0324	CbGpPWpGaD
Rivaroxaban—CYP2J2—Tryptophan metabolism—CYP3A4—bone cancer	0.00199	0.0279	CbGpPWpGaD
Rivaroxaban—F10—Beta2 integrin cell surface interactions—PLAU—bone cancer	0.00192	0.0269	CbGpPWpGaD
Rivaroxaban—F10—Post-translational protein modification—MOGS—bone cancer	0.00189	0.0264	CbGpPWpGaD
Rivaroxaban—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00176	0.0246	CbGpPWpGaD
Rivaroxaban—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00165	0.023	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.00164	0.023	CbGpPWpGaD
Rivaroxaban—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00161	0.0226	CbGpPWpGaD
Rivaroxaban—CYP2J2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00159	0.0223	CbGpPWpGaD
Rivaroxaban—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.00149	0.0208	CbGpPWpGaD
Rivaroxaban—CYP2J2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00131	0.0183	CbGpPWpGaD
Rivaroxaban—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.00117	0.0163	CbGpPWpGaD
Rivaroxaban—Blood lactate dehydrogenase increased—Epirubicin—bone cancer	0.00115	0.0106	CcSEcCtD
Rivaroxaban—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.00112	0.0157	CbGpPWpGaD
Rivaroxaban—Gingival bleeding—Doxorubicin—bone cancer	0.00109	0.01	CcSEcCtD
Rivaroxaban—F10—Complement and Coagulation Cascades—PLAU—bone cancer	0.00109	0.0152	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00108	0.0151	CbGpPWpGaD
Rivaroxaban—Thrombocytosis—Epirubicin—bone cancer	0.00108	0.00986	CcSEcCtD
Rivaroxaban—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.00108	0.0151	CbGpPWpGaD
Rivaroxaban—Blood lactate dehydrogenase increased—Doxorubicin—bone cancer	0.00107	0.00977	CcSEcCtD
Rivaroxaban—Renal failure acute—Cisplatin—bone cancer	0.00102	0.00939	CcSEcCtD
Rivaroxaban—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00101	0.0142	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000997	0.014	CbGpPWpGaD
Rivaroxaban—Thrombocytosis—Doxorubicin—bone cancer	0.000996	0.00913	CcSEcCtD
Rivaroxaban—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000961	0.0135	CbGpPWpGaD
Rivaroxaban—Gastrointestinal haemorrhage—Cisplatin—bone cancer	0.000946	0.00867	CcSEcCtD
Rivaroxaban—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000945	0.0132	CbGpPWpGaD
Rivaroxaban—Blister—Epirubicin—bone cancer	0.000928	0.00851	CcSEcCtD
Rivaroxaban—CYP2J2—Tryptophan metabolism—MDM2—bone cancer	0.000916	0.0128	CbGpPWpGaD
Rivaroxaban—Dermatitis atopic—Epirubicin—bone cancer	0.000904	0.00829	CcSEcCtD
Rivaroxaban—Haemoptysis—Epirubicin—bone cancer	0.000904	0.00829	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—MOGS—bone cancer	0.000896	0.0125	CbGpPWpGaD
Rivaroxaban—Blood creatinine increased—Cisplatin—bone cancer	0.000886	0.00812	CcSEcCtD
Rivaroxaban—Blister—Doxorubicin—bone cancer	0.000859	0.00787	CcSEcCtD
Rivaroxaban—Haemoptysis—Doxorubicin—bone cancer	0.000836	0.00767	CcSEcCtD
Rivaroxaban—Dermatitis atopic—Doxorubicin—bone cancer	0.000836	0.00767	CcSEcCtD
Rivaroxaban—CYP2J2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000826	0.0116	CbGpPWpGaD
Rivaroxaban—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000768	0.0107	CbGpPWpGaD
Rivaroxaban—Rectal haemorrhage—Epirubicin—bone cancer	0.000741	0.00679	CcSEcCtD
Rivaroxaban—Renal failure—Cisplatin—bone cancer	0.000716	0.00657	CcSEcCtD
Rivaroxaban—Blood bilirubin increased—Epirubicin—bone cancer	0.000707	0.00649	CcSEcCtD
Rivaroxaban—CYP2J2—Biological oxidations—CYP3A4—bone cancer	0.000694	0.00971	CbGpPWpGaD
Rivaroxaban—Hepatobiliary disease—Cisplatin—bone cancer	0.000689	0.00632	CcSEcCtD
Rivaroxaban—Rectal haemorrhage—Doxorubicin—bone cancer	0.000685	0.00628	CcSEcCtD
Rivaroxaban—CYP2J2—Metapathway biotransformation—CYP3A4—bone cancer	0.000684	0.00958	CbGpPWpGaD
Rivaroxaban—Blood bilirubin increased—Doxorubicin—bone cancer	0.000655	0.006	CcSEcCtD
Rivaroxaban—Ecchymosis—Methotrexate—bone cancer	0.000646	0.00593	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Cisplatin—bone cancer	0.000646	0.00592	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Cisplatin—bone cancer	0.000643	0.00589	CcSEcCtD
Rivaroxaban—Urethral disorder—Cisplatin—bone cancer	0.000641	0.00588	CcSEcCtD
Rivaroxaban—Blood urea increased—Epirubicin—bone cancer	0.000632	0.00579	CcSEcCtD
Rivaroxaban—Eye disorder—Cisplatin—bone cancer	0.000611	0.00561	CcSEcCtD
Rivaroxaban—Cardiac disorder—Cisplatin—bone cancer	0.000607	0.00557	CcSEcCtD
Rivaroxaban—Ecchymosis—Epirubicin—bone cancer	0.000605	0.00555	CcSEcCtD
Rivaroxaban—CYP2J2—Biological oxidations—GSTP1—bone cancer	0.000593	0.00831	CbGpPWpGaD
Rivaroxaban—Immune system disorder—Cisplatin—bone cancer	0.000591	0.00542	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Cisplatin—bone cancer	0.00059	0.00541	CcSEcCtD
Rivaroxaban—CYP2J2—Metapathway biotransformation—GSTP1—bone cancer	0.000585	0.00819	CbGpPWpGaD
Rivaroxaban—Blood urea increased—Doxorubicin—bone cancer	0.000585	0.00536	CcSEcCtD
Rivaroxaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000582	0.00815	CbGpPWpGaD
Rivaroxaban—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000579	0.00811	CbGpPWpGaD
Rivaroxaban—Renal failure acute—Methotrexate—bone cancer	0.000562	0.00515	CcSEcCtD
Rivaroxaban—Ecchymosis—Doxorubicin—bone cancer	0.00056	0.00513	CcSEcCtD
Rivaroxaban—Hepatic function abnormal—Epirubicin—bone cancer	0.000556	0.00509	CcSEcCtD
Rivaroxaban—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000552	0.00773	CbGpPWpGaD
Rivaroxaban—Muscle spasms—Cisplatin—bone cancer	0.000548	0.00502	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Cisplatin—bone cancer	0.000528	0.00484	CcSEcCtD
Rivaroxaban—Anaemia—Cisplatin—bone cancer	0.000526	0.00483	CcSEcCtD
Rivaroxaban—Renal failure acute—Epirubicin—bone cancer	0.000526	0.00482	CcSEcCtD
Rivaroxaban—Osteoarthritis—Methotrexate—bone cancer	0.000519	0.00476	CcSEcCtD
Rivaroxaban—Hepatic function abnormal—Doxorubicin—bone cancer	0.000514	0.00471	CcSEcCtD
Rivaroxaban—Malaise—Cisplatin—bone cancer	0.000514	0.00471	CcSEcCtD
Rivaroxaban—Dermatitis bullous—Epirubicin—bone cancer	0.000508	0.00466	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—TUBB4B—bone cancer	0.000491	0.00687	CbGpPWpGaD
Rivaroxaban—Renal failure acute—Doxorubicin—bone cancer	0.000487	0.00446	CcSEcCtD
Rivaroxaban—Pain in extremity—Epirubicin—bone cancer	0.000486	0.00445	CcSEcCtD
Rivaroxaban—Osteoarthritis—Epirubicin—bone cancer	0.000486	0.00445	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.000486	0.00445	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000482	0.00441	CcSEcCtD
Rivaroxaban—Discomfort—Cisplatin—bone cancer	0.000479	0.00439	CcSEcCtD
Rivaroxaban—Dermatitis bullous—Doxorubicin—bone cancer	0.00047	0.00431	CcSEcCtD
Rivaroxaban—Oedema—Cisplatin—bone cancer	0.000465	0.00426	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Cisplatin—bone cancer	0.000465	0.00426	CcSEcCtD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000464	0.0065	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000464	0.00649	CbGpPWpGaD
Rivaroxaban—Infection—Cisplatin—bone cancer	0.000462	0.00423	CcSEcCtD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000458	0.00642	CbGpPWpGaD
Rivaroxaban—Nervous system disorder—Cisplatin—bone cancer	0.000456	0.00418	CcSEcCtD
Rivaroxaban—Blood creatinine increased—Epirubicin—bone cancer	0.000455	0.00417	CcSEcCtD
Rivaroxaban—Tachycardia—Cisplatin—bone cancer	0.000454	0.00416	CcSEcCtD
Rivaroxaban—Skin disorder—Cisplatin—bone cancer	0.000452	0.00414	CcSEcCtD
Rivaroxaban—Osteoarthritis—Doxorubicin—bone cancer	0.000449	0.00412	CcSEcCtD
Rivaroxaban—Pain in extremity—Doxorubicin—bone cancer	0.000449	0.00412	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000449	0.00412	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Epirubicin—bone cancer	0.000444	0.00407	CcSEcCtD
Rivaroxaban—Hypotension—Cisplatin—bone cancer	0.000434	0.00398	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—TUBB2A—bone cancer	0.000424	0.00593	CbGpPWpGaD
Rivaroxaban—Blood creatinine increased—Doxorubicin—bone cancer	0.000421	0.00386	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—NDUFA12—bone cancer	0.000416	0.00582	CbGpPWpGaD
Rivaroxaban—Dyspnoea—Cisplatin—bone cancer	0.000414	0.0038	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Doxorubicin—bone cancer	0.00041	0.00376	CcSEcCtD
Rivaroxaban—Angina pectoris—Epirubicin—bone cancer	0.000409	0.00375	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Cisplatin—bone cancer	0.000401	0.00368	CcSEcCtD
Rivaroxaban—Infestation—Methotrexate—bone cancer	0.0004	0.00367	CcSEcCtD
Rivaroxaban—Infestation NOS—Methotrexate—bone cancer	0.0004	0.00367	CcSEcCtD
Rivaroxaban—Pain—Cisplatin—bone cancer	0.000398	0.00364	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000397	0.00364	CcSEcCtD
Rivaroxaban—Renal failure—Methotrexate—bone cancer	0.000393	0.0036	CcSEcCtD
Rivaroxaban—Feeling abnormal—Cisplatin—bone cancer	0.000383	0.00351	CcSEcCtD
Rivaroxaban—Haematuria—Methotrexate—bone cancer	0.000381	0.0035	CcSEcCtD
Rivaroxaban—Angina pectoris—Doxorubicin—bone cancer	0.000378	0.00347	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Methotrexate—bone cancer	0.000378	0.00347	CcSEcCtD
Rivaroxaban—Epistaxis—Methotrexate—bone cancer	0.000377	0.00346	CcSEcCtD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000376	0.00527	CbGpPWpGaD
Rivaroxaban—Infestation NOS—Epirubicin—bone cancer	0.000374	0.00343	CcSEcCtD
Rivaroxaban—Infestation—Epirubicin—bone cancer	0.000374	0.00343	CcSEcCtD
Rivaroxaban—Agranulocytosis—Methotrexate—bone cancer	0.000373	0.00342	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000371	0.0034	CcSEcCtD
Rivaroxaban—Renal failure—Epirubicin—bone cancer	0.000368	0.00337	CcSEcCtD
Rivaroxaban—Jaundice—Epirubicin—bone cancer	0.000365	0.00334	CcSEcCtD
Rivaroxaban—Urinary tract infection—Epirubicin—bone cancer	0.000364	0.00334	CcSEcCtD
Rivaroxaban—Haemoglobin—Methotrexate—bone cancer	0.000361	0.00331	CcSEcCtD
Rivaroxaban—Haemorrhage—Methotrexate—bone cancer	0.000359	0.00329	CcSEcCtD
Rivaroxaban—Hepatitis—Methotrexate—bone cancer	0.000359	0.00329	CcSEcCtD
Rivaroxaban—F10—Hemostasis—SPARC—bone cancer	0.000359	0.00502	CbGpPWpGaD
Rivaroxaban—Haematuria—Epirubicin—bone cancer	0.000357	0.00327	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Methotrexate—bone cancer	0.000355	0.00325	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Epirubicin—bone cancer	0.000354	0.00325	CcSEcCtD
Rivaroxaban—Epistaxis—Epirubicin—bone cancer	0.000353	0.00324	CcSEcCtD
Rivaroxaban—Urethral disorder—Methotrexate—bone cancer	0.000352	0.00323	CcSEcCtD
Rivaroxaban—Sinusitis—Epirubicin—bone cancer	0.000351	0.00322	CcSEcCtD
Rivaroxaban—Agranulocytosis—Epirubicin—bone cancer	0.000349	0.0032	CcSEcCtD
Rivaroxaban—Infestation NOS—Doxorubicin—bone cancer	0.000346	0.00317	CcSEcCtD
Rivaroxaban—Infestation—Doxorubicin—bone cancer	0.000346	0.00317	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—NT5C3A—bone cancer	0.000345	0.00482	CbGpPWpGaD
Rivaroxaban—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000343	0.00315	CcSEcCtD
Rivaroxaban—Hypersensitivity—Cisplatin—bone cancer	0.000342	0.00314	CcSEcCtD
Rivaroxaban—Renal failure—Doxorubicin—bone cancer	0.00034	0.00312	CcSEcCtD
Rivaroxaban—Erythema multiforme—Methotrexate—bone cancer	0.000339	0.00311	CcSEcCtD
Rivaroxaban—Haemoglobin—Epirubicin—bone cancer	0.000338	0.0031	CcSEcCtD
Rivaroxaban—Jaundice—Doxorubicin—bone cancer	0.000338	0.00309	CcSEcCtD
Rivaroxaban—Urinary tract infection—Doxorubicin—bone cancer	0.000337	0.00309	CcSEcCtD
Rivaroxaban—Haemorrhage—Epirubicin—bone cancer	0.000336	0.00308	CcSEcCtD
Rivaroxaban—Hepatitis—Epirubicin—bone cancer	0.000336	0.00308	CcSEcCtD
Rivaroxaban—Eye disorder—Methotrexate—bone cancer	0.000336	0.00308	CcSEcCtD
Rivaroxaban—Asthenia—Cisplatin—bone cancer	0.000334	0.00306	CcSEcCtD
Rivaroxaban—Cardiac disorder—Methotrexate—bone cancer	0.000333	0.00305	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Epirubicin—bone cancer	0.000332	0.00304	CcSEcCtD
Rivaroxaban—Haematuria—Doxorubicin—bone cancer	0.00033	0.00303	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Epirubicin—bone cancer	0.00033	0.00303	CcSEcCtD
Rivaroxaban—Urethral disorder—Epirubicin—bone cancer	0.000329	0.00302	CcSEcCtD
Rivaroxaban—F10—Hemostasis—GNA11—bone cancer	0.000328	0.00459	CbGpPWpGaD
Rivaroxaban—Hepatobiliary disease—Doxorubicin—bone cancer	0.000328	0.003	CcSEcCtD
Rivaroxaban—Epistaxis—Doxorubicin—bone cancer	0.000327	0.00299	CcSEcCtD
Rivaroxaban—Angiopathy—Methotrexate—bone cancer	0.000326	0.00299	CcSEcCtD
Rivaroxaban—Sinusitis—Doxorubicin—bone cancer	0.000325	0.00298	CcSEcCtD
Rivaroxaban—Immune system disorder—Methotrexate—bone cancer	0.000324	0.00297	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Methotrexate—bone cancer	0.000324	0.00297	CcSEcCtD
Rivaroxaban—Agranulocytosis—Doxorubicin—bone cancer	0.000323	0.00296	CcSEcCtD
Rivaroxaban—Diarrhoea—Cisplatin—bone cancer	0.000318	0.00292	CcSEcCtD
Rivaroxaban—Erythema multiforme—Epirubicin—bone cancer	0.000318	0.00291	CcSEcCtD
Rivaroxaban—Eye disorder—Epirubicin—bone cancer	0.000314	0.00288	CcSEcCtD
Rivaroxaban—Haemoglobin—Doxorubicin—bone cancer	0.000312	0.00286	CcSEcCtD
Rivaroxaban—Cardiac disorder—Epirubicin—bone cancer	0.000312	0.00286	CcSEcCtD
Rivaroxaban—Hepatitis—Doxorubicin—bone cancer	0.000311	0.00285	CcSEcCtD
Rivaroxaban—Haemorrhage—Doxorubicin—bone cancer	0.000311	0.00285	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Doxorubicin—bone cancer	0.000307	0.00281	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Doxorubicin—bone cancer	0.000306	0.0028	CcSEcCtD
Rivaroxaban—Angiopathy—Epirubicin—bone cancer	0.000305	0.00279	CcSEcCtD
Rivaroxaban—Urethral disorder—Doxorubicin—bone cancer	0.000305	0.00279	CcSEcCtD
Rivaroxaban—Immune system disorder—Epirubicin—bone cancer	0.000304	0.00278	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Epirubicin—bone cancer	0.000303	0.00278	CcSEcCtD
Rivaroxaban—Back pain—Methotrexate—bone cancer	0.000302	0.00277	CcSEcCtD
Rivaroxaban—F10—Hemostasis—IL3—bone cancer	0.000297	0.00416	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—EIF2S1—bone cancer	0.000296	0.00414	CbGpPWpGaD
Rivaroxaban—Vomiting—Cisplatin—bone cancer	0.000296	0.00271	CcSEcCtD
Rivaroxaban—Erythema multiforme—Doxorubicin—bone cancer	0.000294	0.00269	CcSEcCtD
Rivaroxaban—Rash—Cisplatin—bone cancer	0.000293	0.00269	CcSEcCtD
Rivaroxaban—Dermatitis—Cisplatin—bone cancer	0.000293	0.00268	CcSEcCtD
Rivaroxaban—Eye disorder—Doxorubicin—bone cancer	0.000291	0.00266	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Methotrexate—bone cancer	0.00029	0.00266	CcSEcCtD
Rivaroxaban—Anaemia—Methotrexate—bone cancer	0.000289	0.00265	CcSEcCtD
Rivaroxaban—Cardiac disorder—Doxorubicin—bone cancer	0.000289	0.00265	CcSEcCtD
Rivaroxaban—Back pain—Epirubicin—bone cancer	0.000283	0.00259	CcSEcCtD
Rivaroxaban—Angiopathy—Doxorubicin—bone cancer	0.000282	0.00259	CcSEcCtD
Rivaroxaban—Malaise—Methotrexate—bone cancer	0.000282	0.00258	CcSEcCtD
Rivaroxaban—Muscle spasms—Epirubicin—bone cancer	0.000281	0.00258	CcSEcCtD
Rivaroxaban—Immune system disorder—Doxorubicin—bone cancer	0.000281	0.00257	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Doxorubicin—bone cancer	0.00028	0.00257	CcSEcCtD
Rivaroxaban—Nausea—Cisplatin—bone cancer	0.000276	0.00253	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Epirubicin—bone cancer	0.000271	0.00249	CcSEcCtD
Rivaroxaban—Anaemia—Epirubicin—bone cancer	0.00027	0.00248	CcSEcCtD
Rivaroxaban—Chest pain—Methotrexate—bone cancer	0.000266	0.00244	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000264	0.00242	CcSEcCtD
Rivaroxaban—Malaise—Epirubicin—bone cancer	0.000264	0.00242	CcSEcCtD
Rivaroxaban—Discomfort—Methotrexate—bone cancer	0.000263	0.00241	CcSEcCtD
Rivaroxaban—Syncope—Epirubicin—bone cancer	0.000262	0.0024	CcSEcCtD
Rivaroxaban—Back pain—Doxorubicin—bone cancer	0.000262	0.0024	CcSEcCtD
Rivaroxaban—Muscle spasms—Doxorubicin—bone cancer	0.00026	0.00239	CcSEcCtD
Rivaroxaban—Loss of consciousness—Epirubicin—bone cancer	0.000257	0.00236	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Methotrexate—bone cancer	0.000255	0.00234	CcSEcCtD
Rivaroxaban—Infection—Methotrexate—bone cancer	0.000253	0.00232	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Doxorubicin—bone cancer	0.000251	0.0023	CcSEcCtD
Rivaroxaban—Nervous system disorder—Methotrexate—bone cancer	0.00025	0.00229	CcSEcCtD
Rivaroxaban—Anaemia—Doxorubicin—bone cancer	0.00025	0.00229	CcSEcCtD
Rivaroxaban—Chest pain—Epirubicin—bone cancer	0.000249	0.00228	CcSEcCtD
Rivaroxaban—Skin disorder—Methotrexate—bone cancer	0.000248	0.00227	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000247	0.00227	CcSEcCtD
Rivaroxaban—Discomfort—Epirubicin—bone cancer	0.000246	0.00226	CcSEcCtD
Rivaroxaban—Malaise—Doxorubicin—bone cancer	0.000244	0.00224	CcSEcCtD
Rivaroxaban—Dry mouth—Epirubicin—bone cancer	0.000244	0.00223	CcSEcCtD
Rivaroxaban—Syncope—Doxorubicin—bone cancer	0.000243	0.00222	CcSEcCtD
Rivaroxaban—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.00024	0.00337	CbGpPWpGaD
Rivaroxaban—Oedema—Epirubicin—bone cancer	0.000239	0.00219	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Epirubicin—bone cancer	0.000239	0.00219	CcSEcCtD
Rivaroxaban—Hypotension—Methotrexate—bone cancer	0.000238	0.00219	CcSEcCtD
Rivaroxaban—Loss of consciousness—Doxorubicin—bone cancer	0.000238	0.00218	CcSEcCtD
Rivaroxaban—Infection—Epirubicin—bone cancer	0.000237	0.00217	CcSEcCtD
Rivaroxaban—Shock—Epirubicin—bone cancer	0.000235	0.00215	CcSEcCtD
Rivaroxaban—Nervous system disorder—Epirubicin—bone cancer	0.000234	0.00215	CcSEcCtD
Rivaroxaban—Tachycardia—Epirubicin—bone cancer	0.000233	0.00214	CcSEcCtD
Rivaroxaban—Skin disorder—Epirubicin—bone cancer	0.000232	0.00213	CcSEcCtD
Rivaroxaban—Chest pain—Doxorubicin—bone cancer	0.00023	0.00211	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000229	0.0021	CcSEcCtD
Rivaroxaban—Discomfort—Doxorubicin—bone cancer	0.000228	0.00209	CcSEcCtD
Rivaroxaban—Dyspnoea—Methotrexate—bone cancer	0.000227	0.00208	CcSEcCtD
Rivaroxaban—Dry mouth—Doxorubicin—bone cancer	0.000225	0.00207	CcSEcCtD
Rivaroxaban—Dyspepsia—Methotrexate—bone cancer	0.000225	0.00206	CcSEcCtD
Rivaroxaban—Hypotension—Epirubicin—bone cancer	0.000223	0.00204	CcSEcCtD
Rivaroxaban—Oedema—Doxorubicin—bone cancer	0.000221	0.00202	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Doxorubicin—bone cancer	0.000221	0.00202	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Methotrexate—bone cancer	0.00022	0.00202	CcSEcCtD
Rivaroxaban—Fatigue—Methotrexate—bone cancer	0.00022	0.00202	CcSEcCtD
Rivaroxaban—Infection—Doxorubicin—bone cancer	0.000219	0.00201	CcSEcCtD
Rivaroxaban—Pain—Methotrexate—bone cancer	0.000218	0.002	CcSEcCtD
Rivaroxaban—Shock—Doxorubicin—bone cancer	0.000217	0.00199	CcSEcCtD
Rivaroxaban—Nervous system disorder—Doxorubicin—bone cancer	0.000217	0.00199	CcSEcCtD
Rivaroxaban—Tachycardia—Doxorubicin—bone cancer	0.000216	0.00198	CcSEcCtD
Rivaroxaban—Skin disorder—Doxorubicin—bone cancer	0.000215	0.00197	CcSEcCtD
Rivaroxaban—Dyspnoea—Epirubicin—bone cancer	0.000213	0.00195	CcSEcCtD
Rivaroxaban—Feeling abnormal—Methotrexate—bone cancer	0.00021	0.00193	CcSEcCtD
Rivaroxaban—Dyspepsia—Epirubicin—bone cancer	0.00021	0.00193	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Methotrexate—bone cancer	0.000209	0.00191	CcSEcCtD
Rivaroxaban—Hypotension—Doxorubicin—bone cancer	0.000206	0.00189	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Epirubicin—bone cancer	0.000206	0.00189	CcSEcCtD
Rivaroxaban—Fatigue—Epirubicin—bone cancer	0.000206	0.00189	CcSEcCtD
Rivaroxaban—Constipation—Epirubicin—bone cancer	0.000204	0.00187	CcSEcCtD
Rivaroxaban—Pain—Epirubicin—bone cancer	0.000204	0.00187	CcSEcCtD
Rivaroxaban—Urticaria—Methotrexate—bone cancer	0.000203	0.00186	CcSEcCtD
Rivaroxaban—Abdominal pain—Methotrexate—bone cancer	0.000202	0.00185	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.0002	0.0028	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000197	0.00276	CbGpPWpGaD
Rivaroxaban—Dyspnoea—Doxorubicin—bone cancer	0.000197	0.00181	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000197	0.00276	CbGpPWpGaD
Rivaroxaban—Feeling abnormal—Epirubicin—bone cancer	0.000197	0.0018	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Epirubicin—bone cancer	0.000195	0.00179	CcSEcCtD
Rivaroxaban—F10—Hemostasis—PLAU—bone cancer	0.000195	0.00273	CbGpPWpGaD
Rivaroxaban—Dyspepsia—Doxorubicin—bone cancer	0.000194	0.00178	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000191	0.00175	CcSEcCtD
Rivaroxaban—Fatigue—Doxorubicin—bone cancer	0.00019	0.00175	CcSEcCtD
Rivaroxaban—Urticaria—Epirubicin—bone cancer	0.00019	0.00174	CcSEcCtD
Rivaroxaban—Constipation—Doxorubicin—bone cancer	0.000189	0.00173	CcSEcCtD
Rivaroxaban—Pain—Doxorubicin—bone cancer	0.000189	0.00173	CcSEcCtD
Rivaroxaban—Abdominal pain—Epirubicin—bone cancer	0.000189	0.00173	CcSEcCtD
Rivaroxaban—Hypersensitivity—Methotrexate—bone cancer	0.000188	0.00172	CcSEcCtD
Rivaroxaban—Asthenia—Methotrexate—bone cancer	0.000183	0.00168	CcSEcCtD
Rivaroxaban—Feeling abnormal—Doxorubicin—bone cancer	0.000182	0.00167	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Doxorubicin—bone cancer	0.000181	0.00166	CcSEcCtD
Rivaroxaban—Pruritus—Methotrexate—bone cancer	0.00018	0.00165	CcSEcCtD
Rivaroxaban—Hypersensitivity—Epirubicin—bone cancer	0.000176	0.00161	CcSEcCtD
Rivaroxaban—Urticaria—Doxorubicin—bone cancer	0.000175	0.00161	CcSEcCtD
Rivaroxaban—Abdominal pain—Doxorubicin—bone cancer	0.000175	0.0016	CcSEcCtD
Rivaroxaban—Diarrhoea—Methotrexate—bone cancer	0.000175	0.0016	CcSEcCtD
Rivaroxaban—Asthenia—Epirubicin—bone cancer	0.000171	0.00157	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000171	0.00239	CbGpPWpGaD
Rivaroxaban—Pruritus—Epirubicin—bone cancer	0.000169	0.00155	CcSEcCtD
Rivaroxaban—Dizziness—Methotrexate—bone cancer	0.000169	0.00155	CcSEcCtD
Rivaroxaban—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000169	0.00236	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000167	0.00234	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Epirubicin—bone cancer	0.000163	0.0015	CcSEcCtD
Rivaroxaban—Hypersensitivity—Doxorubicin—bone cancer	0.000163	0.00149	CcSEcCtD
Rivaroxaban—Vomiting—Methotrexate—bone cancer	0.000162	0.00149	CcSEcCtD
Rivaroxaban—Rash—Methotrexate—bone cancer	0.000161	0.00147	CcSEcCtD
Rivaroxaban—Dermatitis—Methotrexate—bone cancer	0.000161	0.00147	CcSEcCtD
Rivaroxaban—Headache—Methotrexate—bone cancer	0.00016	0.00146	CcSEcCtD
Rivaroxaban—Asthenia—Doxorubicin—bone cancer	0.000158	0.00145	CcSEcCtD
Rivaroxaban—Dizziness—Epirubicin—bone cancer	0.000158	0.00145	CcSEcCtD
Rivaroxaban—Pruritus—Doxorubicin—bone cancer	0.000156	0.00143	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000152	0.00213	CbGpPWpGaD
Rivaroxaban—Vomiting—Epirubicin—bone cancer	0.000152	0.00139	CcSEcCtD
Rivaroxaban—Nausea—Methotrexate—bone cancer	0.000152	0.00139	CcSEcCtD
Rivaroxaban—Diarrhoea—Doxorubicin—bone cancer	0.000151	0.00139	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—ENO2—bone cancer	0.000151	0.00211	CbGpPWpGaD
Rivaroxaban—Rash—Epirubicin—bone cancer	0.000151	0.00138	CcSEcCtD
Rivaroxaban—Dermatitis—Epirubicin—bone cancer	0.00015	0.00138	CcSEcCtD
Rivaroxaban—Headache—Epirubicin—bone cancer	0.00015	0.00137	CcSEcCtD
Rivaroxaban—Dizziness—Doxorubicin—bone cancer	0.000146	0.00134	CcSEcCtD
Rivaroxaban—Nausea—Epirubicin—bone cancer	0.000142	0.0013	CcSEcCtD
Rivaroxaban—Vomiting—Doxorubicin—bone cancer	0.00014	0.00129	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—DHFR—bone cancer	0.00014	0.00196	CbGpPWpGaD
Rivaroxaban—Rash—Doxorubicin—bone cancer	0.000139	0.00128	CcSEcCtD
Rivaroxaban—Dermatitis—Doxorubicin—bone cancer	0.000139	0.00128	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000139	0.00194	CbGpPWpGaD
Rivaroxaban—Headache—Doxorubicin—bone cancer	0.000138	0.00127	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000137	0.00192	CbGpPWpGaD
Rivaroxaban—Nausea—Doxorubicin—bone cancer	0.000131	0.0012	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—GNA11—bone cancer	0.000131	0.00183	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	0.00013	0.00182	CbGpPWpGaD
Rivaroxaban—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000123	0.00172	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—MMP2—bone cancer	0.000121	0.00169	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NDUFA12—bone cancer	0.00012	0.00168	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CYP3A4—bone cancer	0.000119	0.00166	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000118	0.00165	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000116	0.00162	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000116	0.00162	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSTP1—bone cancer	0.000101	0.00142	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.99e-05	0.0014	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NT5C3A—bone cancer	9.93e-05	0.00139	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NDUFA12—bone cancer	9.04e-05	0.00127	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	8.6e-05	0.0012	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GSTP1—bone cancer	7.95e-05	0.00111	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	7.84e-05	0.0011	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TP53—bone cancer	7.84e-05	0.0011	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NT5C3A—bone cancer	7.49e-05	0.00105	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	6.38e-05	0.000893	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	6.15e-05	0.000861	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NDUFA12—bone cancer	5.57e-05	0.00078	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	5.54e-05	0.000776	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTGS2—bone cancer	5.26e-05	0.000736	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NT5C3A—bone cancer	4.62e-05	0.000646	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.36e-05	0.00061	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ENO2—bone cancer	4.35e-05	0.000609	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—DHFR—bone cancer	4.04e-05	0.000565	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GNA11—bone cancer	3.77e-05	0.000528	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.66e-05	0.000512	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP3A4—bone cancer	3.42e-05	0.000479	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ENO2—bone cancer	3.28e-05	0.00046	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—DHFR—bone cancer	3.05e-05	0.000426	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTP1—bone cancer	2.92e-05	0.000409	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GNA11—bone cancer	2.85e-05	0.000398	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP3A4—bone cancer	2.58e-05	0.000361	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTP1—bone cancer	2.21e-05	0.000309	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ENO2—bone cancer	2.02e-05	0.000283	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—DHFR—bone cancer	1.88e-05	0.000263	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GNA11—bone cancer	1.75e-05	0.000245	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTGS2—bone cancer	1.52e-05	0.000212	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTP1—bone cancer	1.36e-05	0.00019	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTGS2—bone cancer	1.14e-05	0.00016	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTGS2—bone cancer	7.04e-06	9.86e-05	CbGpPWpGaD
